Tentative Program

8th World Congress on Bioavailability and Bioequivalence:
Pharmaceutical R & D Summit

June 26-27, 2017 San Diego, California, USA

Interactive Sessions  Keynote Lectures  Plenary Lectures  Workshops
Exhibitors  B2B Meetings

***For available speaker slots***

ba.be@pharmaceuticalconferences.org

http://bioavailability-bioequivalence.pharmaceuticalconferences.com/
# 8th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit

**26-27, 2017**  San Diego, USA

## Program at a Glance

### Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>General Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td>Inaugural Address</td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>Least of 3 Keynote/Plenary Talks</td>
</tr>
<tr>
<td>09.15-09.45</td>
<td>Keynote/Plenary Talk 1</td>
</tr>
<tr>
<td>09.45-10.15</td>
<td>Keynote/Plenary Talk 2</td>
</tr>
<tr>
<td>10.15-10.45</td>
<td>Keynote/Plenary Talk 3</td>
</tr>
<tr>
<td></td>
<td>Panel Discussions/Group Photo</td>
</tr>
<tr>
<td>11.00-12.40</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
<tr>
<td>13.25-15.05</td>
<td>6 Speakers (20 Mins Each)</td>
</tr>
<tr>
<td>15.45-17.25</td>
<td>Coffee/Tea Break 15.30-15.45 (Networking)</td>
</tr>
</tbody>
</table>

### Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
<tr>
<td>10.55-12.35</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
<tr>
<td>13.25-15.05</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
<tr>
<td>15.20-17.00</td>
<td>5 Speakers (20 Mins Each)</td>
<td>5 Speakers (20 Mins Each)</td>
</tr>
</tbody>
</table>

### Awards & Closing Ceremony

**NOTE:** Program Schedule is subject to change with final allotment of the speaker slots

For more Details PS: [http://bioavailability-bioequivalence.pharmaceuticalconferences.com](http://bioavailability-bioequivalence.pharmaceuticalconferences.com)  
Email: ba.be@pharmaceuticalconferences.org

Significance of BA/BE Studies
Advances in BABE
Bioavailability Studies
Bioequivalence Studies
Factors Affecting Bioavailability
Assessment of Bioequivalence
Managing BA/BE Studies
Regulatory Requirements for Bioequivalence
Study Designs
Bioequivalence Protocols: In vivo/In vitro studies

Nutrient Bioavailability
BA/BE of biologics & Biosimilars
Clinical Trials
Pharma Clinical Trials
Contract Research Organizations
Challenges in Drug Design
Challenges in Drug Development
Clinical Pharmacology and Therapeutics
Pharmaceutical Industry: Entrepreneurs Investment Meet

Best Poster Award

- You will be given about 5-7 minutes to present your poster including questions and answers. Judges may pose questions during the evaluation of the poster.
- Judges will even evaluate the student’s enthusiasm towards their study, interest and knowledge in the area of their research.
- The winners will be announced at the closing ceremony of the conference. The decision of the winner will be withdrawn if the winner/winner is/are not present at the time of announcement.

Apart from the judging time you may also be present at the poster to share your research with interested delegates.

Young Researchers Forum

- Present your research through oral presentations.
- Learn about career development and the latest research tools and technologies in your field.
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research.
- Develop a foundation for collaboration among young researchers.
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe.
- Interact and share ideas with both peers and mentors.

General Queries
ba.be@pharmaceuticalconferences.org

Conference Venue
San Diego, California, USA

Contact us
America: Conference Series LLC
BABE 2017
57 Ullswater Avenue, West End, Southampton, Hampshire, United Kingdom, SO18 3QS
Tel: +1-888-843-8169, Fax: +1-650-618-1417
Email: ba.be@pharmaceuticalconferences.org

Contact us
UK: Conference Series LLC
BABE 2017
40 Bloomsbury Way Bloomsbury Way, Lower Ground Floor, London, England, WC1A 2SE
Tel: +1-800-216-6499
Email: ba.be@pharmaceuticalconferences.org

Contact us
Asia-Pacific: Conference Series LLC
BABE 2017
Divyasree Building, Raidurg 6th Floor, North Block
Hyderabad 500032, INDIA
Tel: 040-33432309
Email: ba.be@pharmaceuticalconferences.org

For detailed sessions, please visit: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/
Submit your abstract online at: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/abstract-submission.php
Register online: https://www.conferenceseries.com/onlinepayment/
Glimpses of BABE Conferences

http://bioavailability-bioequivalence.pharmaceuticalconferences.com/
Day 1 August 29, 2016

08:30-09:30 Registrations

Hall- Allatoona

09:45-10:05 Opening Ceremony

Keynote Forum

Introduction
Title: Parenteral drug delivery systems for insoluble drugs
Jim Jingjun Huang, Ascendia Pharmaceuticals, USA

Group photo

Networking and Refreshments Break

Title: Hybrid-Nanoengineering™: A new platform for nanomedicine
Mewa Singh, Meda Biotech LLC, USA

Sessions:
Challenges in Drug Development | Bioavailability Studies | Assessment of Bioequivalence | Clinical Pharmacology and Therapeutics

Session Chair: Akwete Lex Adjei, Rhodes Pharmaceuticals LP, USA
Session Co-chair: Muneesh Garg, Sitec Labs. Pvt. Ltd., India

Session Introduction

Title: New analytical methodology in assessing comparability of biosimilars
Julia Ding, PPD Labs, USA

Lunch Break

Title: Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2’-deoxymethylene nucleosides
Khairia M Youssef, Future University, Egypt

Title: Risk assessment with the help of FMEA analysis in BE studies
Kateryna Zupanets, National University of Pharmacy, Ukraine

Title: Some aspects of clinical trials on bioequivalence studies
Kateryna Zupanets, National University of Pharmacy, Ukraine

Title: Bioequivalence of Ipratropium Bromide HFA pMDI 20 μg/ actuation in healthy volunteers with and without charcoal blockade; and with spacer device
Muneesh Garg, Sitec Labs. Pvt. Ltd., India

Networking and Refreshments Break

Panel Discussion

Day 2 August 30, 2016

Hall- Allatoona

Keynote Forum

Title: Steady-state bioavailability of extended-release Methylphenidate capsules vs. immediate-release Methylphenidate tablets in healthy adult volunteers
Akwete Lex Adeji, Rhodes Pharmaceuticals LP, USA

Networking and Refreshments Break

conferenceseries.com
Title: Accelerating preclinical development for poorly bioavailable compounds by assessing multiple oral technologies in parallel
Stephen Tindal, Catalent, USA

Title: Starch-guar gum extrudates: Microstructure, physicochemical properties and in vitro digestion
Erich von Borries Medrano, Instituto Politecnico Nacional, Mexico

Poster Presentations @ 12:15-12:45

BABE-001
Title: Suggestions for stage I of clinical trials of Diclocor
Oleksii Popov, National University of Pharmacy, Ukraine

BABE-002
Title: Micellar liquid chromatographic determination of Lamivudine, Indinavir and Ketoconazole in dosage forms and biological fluids
Wael Talaat, Damanhour University, Egypt

Lunch Break
Title: Overview of bioavailability/bioequivalence clinical trials in a phase 1 in Turkey
Zafer Sezer, Erciyes University, Turkey

Title: Structural approaches for targeted therapy
Somdutta Saha, GlaxoSmithKline, USA

Title: Development of sustained release antifungal, anti/protozoa and antimicrobial products in horses using hydrogels and extended release formulations in veterinary medicine
Sue Duran, Auburn University, USA

Panel Discussion
Day 1 August 17, 2015

Hall-2

Opening Ceremony

Keynote Forum

Introduction
Paramjeet Kaur
U.S. Food and Drug Administration, USA

Workshop
Jim Jingjun Huang
Ascendia Pharmaceuticals, USA

Group Photo

Networking & Refreshments

Track 3: Contemporary Challenges of Drug Design, Discovery and Development
Track 7: Bioavailability, Bioequivalence and Drug Product Selection
Track 11: Clinical Pharmacology and Therapeutics
Track 12: Study Designs

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA
Session Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

Title: Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assay
Keith Gallicano, Novum Pharmaceutical Research Services, USA

Title: Prediction of in-vivo permeability, solubility, BCS-classing, food interactions, fraction absorbed and oral bioavailability using new in-silico methods and algorithms
Urban Fagerholm, Prosilico, Sweden

Lunch Break

13:50-14:20
Title: Discovery of novel scaffolds for PI3-activated kinase 4 inhibitors targeting C-terminal
Dongmei Zhao, Shenyang Pharmaceutical University, China

Track 1: Emerging Bioavailability and Bioequivalence Studies
Track 5: Managing BA/BE Studies
Track 9: Need for Conducting BA/BE Studies
Track 13: Factors Affecting Bioavailability

Session Chair: Paramjeet Kaur, U.S. Food and Drug Administration, USA
Session Co-Chair: Aydın Erenmemisoglu, Novagenix Drug R&D Centre, Turkey

Session Introduction

Title: Optimizing formulation to maximize drug absorption from solution formulations
Wenzhan Yang, Astra Zeneca Pharmaceuticals LP, USA

Title: Design, synthesis and studies of delta and Cox-2 receptor specific analgesic anti-inflammatory activity of some linear and cyclic peptides
Subir Samanta, Birla Institute of Technology, India

Networking & Refreshments

Track 2: Bioanalytical Methodology
Track 4: Regulatory Policies, Procedures and Prerequisites for Clinical Research
Track 6: Relevance of Genetics to BA/BE in Drug Development
Track 8: Advances in Assessment of Bioequivalence
Track 10: Metabolic Pathways and Changes in Nutrient Bioavailability

Panel Discussion

Day 2 August 18, 2015

Hall-2
Session Chair: Subrata Deb, Roosevelt University College of Pharmacy, USA  
Session Co-Chair: Dongmei Zhao, Shenyang Pharmaceutical University, China

Session Introduction

Title: Effect of formulation development and API characteristics on fast dissolving dosage forms bioequivalence studies
Gulay Yelken Demirel, Sanovel Pharmaceuticals, Turkey

Title: Oral bioavailability and gender-related pharmacokinetics of Celastrol following administration of pure celastrol and its related tablets in rats
Wenzheng Ju, Jiangsu Provincial Hospital of Traditional Chinese Medicine, China

Title: Preparation and in-vitro evaluation of meloxicam co-ground mixtures
Aly H Nada, Kuwait University, Kuwait

Networking & Refreshments

Title: Impact of glucocorticoids on the bioavailability and metabolism of Abiraterone and Calcitriol
Subrata Deb, Roosevelt University College of Pharmacy, USA

Title: Comparative analysis, target specificities and plant protection potential of antimicrobial peptides isolated from xenorhabdus species
Andras Fodor, University of Wisconsin-Madison, USA

Lunch Break

Title: E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjects
Muneesh Garg, Sitec Labs Pvt Ltd, India

Title: Eprosartan mesylate cocrystals and their enhanced oral bioavailability studies
Jaswanth Santosh Bhandaru, Kakatiya University, India

Title: In-vitro bioequivalence studies in tablet formulation containing 625mg of Colesevelam hydrochloride
Gulcin Tok, Sanovel Pharmaceuticals, Turkey

Poster Presentations

BA-001 Title: A rapid HPLC method for metoprolol quantification: Application for ex vivo intestinal studies using Franz cells
Andre Bersani Dezani, University of Sao Paulo, Brazil

BA-002 Title: A rapid HPLC method for ranitidine quantification: Application for in situ intestinal perfusion studies
Thaisa Marinho Dezani, University of Sao Paulo, Brazil

BA-003 Title: Patchable thermal responsive ion channel for drug delivery
Kyoung-Yong Chun, Korea University, Republic of South Korea

BA-004 Title: In-vitro bioequivalence studies in tablet formulation containing 625mg of colesevelam hydrochloride
Gulcin Tok, Sanovel Pharmaceuticals, Turkey

BA-005 Title: E-BABE- A bioequivalence study of two Nicotine 2mg Lozenge formulations in healthy adult Indian human male smoker subjects
Muneesh Garg, Sitec Labs Pvt Ltd, India

BA-006 Title: Eprosartan mesylate cocrystals and their enhanced oral bioavailability studies
Jaswanth Santosh Bhandaru, Kakatiya University, India

BA-007 Title: In-vitro bioequivalence study of Tiotropium bromide inhaled drug emitted from Spiriva and Tiova formulations
Abdullah Alturki, King Abdullah International Medical Research Centre, KSA

BA-008 Title: In-vitro bioequivalence study of Tiotropium bromide inhaled drug emitted from Spiriva and Tiova formulations
Salman Abdullah Alfadhel, King Abdullah International Medical Research Centre, KSA

Panel Discussion

Day 3               August 19, 2015
Hall-2

Business to Business Meetings(B2B)

Academics & Research Meetings

Closing Ceremony
Day 1  September 29, 2014

Registrations

Anna Polis

Opening Ceremony

Keynote Forum

Introduction

Sinerik Ayrapetyan
UNESCO, Armenia

Michael Retsky
Harvard School of Health, USA

Georg F Weber
University of Cincinnati Academic Health Center, USA

Coffee Break

Sid Bhoopathy
Absorption Systems, USA

Track 1: Emerging Bioavailability and Bioequivalence Studies
Track 2: Bioanalytical Methodology

Session Introduction

Session Chair: Sinerik Ayrapetyan, UNESCO, Armenia
Session Co-Chair: Yahdiana Harahap, University of Indonesia, Indonesia

Title: Novel approach to enhance oral bioavailability of drugs with poor permeability
Michael Zhuo Wang, University of Kansas, USA

Title: Reversible metabolic complexes for novel drug discovery
Songon An, University of Maryland, Baltimore County, USA

Title: Strategies for establishing equivalence of complex drug products
Sid Bhoopathy, Absorption Systems, USA

Title: Renal elimination of aristolochic acid I in the isolated perfused kidney model
Mariana Babayeva, Touro College of Pharmacy, USA

Title: A bioequivalence study of quetiapine film coated tablets in Indonesian volunteers
Yahdiana Harahap, University of Indonesia, Indonesia

Lunch Break

Title: Intracellular water absorption is a primary sensor for extracellular and intracellular signals
Sinerik Ayrapetyan, UNESCO, Armenia

Title: Expanding BCS-based biowaivers
Lisa J Murray, Provenir, USA

Title: Impact of rHu-Epo supplementation on CRF induced neurobehavioral changes in rats: Studies on correlation with APP ratio, \(\text{\(\beta\)}\) amyloid and pTau expression
P Venkataraman, SRM Medical College, India

Title: Synergism of antibiotics and plant extracts in antibacterial activity against methicillin resistant \(\text{Staphylococcus aureus}\)
Jency Blesson, Sree Buddha College of Engineering, India

Title: Analytical techniques for tracking counterfeit and substandard medicines
Badr Aljohani, Queen Mary University of London, UK

Title: Micrometer-sized giant vesicles composed of amphiphilic random block copolymers prepared by photopolymerization-induced self-assembly
Eri Yoshida, Toyohashi University of Technology, Japan

Coffee Break

Title: Determination of clarithromycin in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry application to bioequivalence studies
Syed N Alvi, King Faisal Specialist Hospital & Research Centre, Saudi Arabia

Title: The challenge of nanomaterial and environmental bioavailability (NEB) measures
Camellia Moses Okpodu, Norfolk State University, USA

Cocktails Sponsored by Journal of Bioequivalence & Bioavailability @ Foyer
### Keynote Forum

**Jim Jingjun Huang**  
Ascendia Pharmaceuticals, USA  

**P Venkataraman**  
SRM Medical College, India

- **Track 3**: Contemporary Challenges of Drug Design, Discovery and Development  
- **Track 6**: Relevance of Genetics to BA/BE in Drug Development  
- **Track 7**: Bioavailability, Bioequivalence and Drug Product Selection  
- **Track 10**: Metabolic Pathways and Changes in Nutrient Bioavailability

**Session Chair:** Dongfeng Tan, The University of Texas MD Anderson Cancer Center, USA  
**Session Co-Chair:** P Venkataraman, SRM Medical College, India

**Title:** Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents  
**Ming-Hua Hsu**, National Tsing Hua University, Taiwan

### Coffee Break

**Title:** In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans  
**Aly H Nada**, Kuwait University, Kuwait

**Title:** Functional Respiratory Imaging (FRI) to assess bio-equivalence of inhaled medication  
**Jan De Backer**, FLUIDDA, Belgium

**Title:** Design of drug delivery system for poorly water soluble drugs with enhanced bioavailability  
**Jim Jingjun Huang**, Ascendia Pharmaceuticals, USA

**Title:** Biobanking and its role in precision medicine  
**Dongfeng Tan**, The University of Texas MD Anderson Cancer Center, USA

**Title:** BCS-Based biowaivers: Which drugs are eligible?  
**Anita Nair**, Merck KGaA, Germany

**Title:** Simulating the suppression of mechanism for the pathogenic *E.coli* resistance to gentamicin  
**I S Korotetskiy**, Scientific Centre for Anti-Infectious Drugs, Kazakhstan

### Lunch Break

**Title:** Plant medicine and veterinary potential of antimicrobial peptides produced by entomopathogenic nematode symbiotic bacteria  
**Habil Andras Fodor**, Ohio State University, USA

**Title:** Chemical degradation of proteins: Novel pathways and products probed during accelerated stability studies  
**Christian Schoneich**, The University of Kansas, USA

**Title:** Development of curcumin solid lipid nanoparticle and assessment of pharmacokinetics and brain availability in Wistar rats  
**Habibur Rahman**, PSG College of Pharmacy, India

**Title:** Chemical modification of anticancer parasporins for decreasing of their toxicity  
**Almas Okassov**, Scientific Center for Anti-Infectious Drugs, Kazakhstan

**Title:** Formulation and evaluation of esomeprazole buccal patch  
**Harsh Shah**, Shankersinh Vaghela Bapu Institute of Pharmacy, India

**Title:** Pharmacogenomics of cancer therapeutics: Molecular structure, drug development and inter-patient variability  
**Salah M Blaih**, Kent State University, USA

### Coffee Break

**Title:** Control and treatment of ehrlich tumors implanted in mice by extremely low frequency electromagnetic waves at resonance frequency  
**Fadel M Ali**, Cairo University, Egypt

**Title:** No,K-ATPase isoform-selective cardiac glycosides: A potential anti-cancer drug?  
**Adriana Katz**, Weizmann Institute of Science, Israel

**Title:** Pharmacokinetics of anti-tuberculosis drug on healthy volunteers: Results from the phase I clinical trial  
**Rinat Islamov**, Scientific Center for Anti-Infectious Drugs, Kazakhstan

**Title:** Efficiency of two-stage designs for crossover bioequivalence trials  
**Sven Schnaidt**, University of Heidelberg, Germany

**Poster Presentations @ Foyer**

Cocktails Sponsored by Journal of Bioanalysis & Biomedicine @ Foyer

---

**Anna Polis**

- **Day 3**: Need for Conducting BA/BE Studies  
- **Track 12**: Clinical Pharmacology and Therapeutics  
- **Track 13**: Translational Cancer Research and Anti-Cancer Drug Discovery
Title: BABE is a beautiful science but why is it only infrequently used in oncology?
Michael Retsky, Harvard School of Public Health, USA

Title: Clinical outcome in patients with cardiovascular pathologies treated with clopidogrel: Impact of genotype profile, clopidogrel metabolites PK and comedication on the clinical results
Luigi Silvestro, 3S-Pharmacological Consultation & Research GmbH, Germany

Title: Mathematical models of RNA expression profiles: Potential applications to drug discovery research and personalized medicine
Sungchul Ji, Rutgers University, USA

Title: Evaluation of the adhesion performance of different transdermal formulations by means of thermography in comparison with the classical visual approach as proposed by FDA
Simona Rizea Savu, 3S-Pharmacological Consultation & Research GmbH, Germany

Title: High-resolution NMR as a higher order structure assessment tool for protein therapeutics
John P Marino, National Institute of Standards and Technology, USA

Coffee Break

Title: Pharmacokinetics and pharmacodynamics of thymoquinone as a novel agent in sepsis management
Khalid M Alkharfy, King Saud University, Saudi Arabia

Title: Cancer characteristics that may compromise drug efficacy
Georg F Weber, University of Cincinnati Academic Health Center, USA

Title: Assessing the bioavailability and bioequivalence of topical dermatologic drug products with multiple surrogate tests
Thomas J Franz, Cetero Research, USA

Title: Effects of carbamazepine on serum levels of folic acid and homocysteine
Hasan Khaled, Damascus University, Syria

Title: Role of Na,K-ATPase in human pancreatic and liver cancer
Peiying Yang, The University of Texas, USA

Title: Isoeugenol accelerates wound healing by attenuating pro-inflammatory markers and chemokine expression in diabetic mice
Tajdar Husain Khan, Salman Bin Abdulaziz University, Saudi Arabia

Lunch Break @ Eden’s Landing Restaurant